Experimental data support a role for FAK, an important component of the integrin signaling pathway, in insulin action. Insulin has been shown to regulate the tyrosine phosphorylation state of FAK in vitro and promotes the association of both insulin receptor substrate-1 (IRS-1) and phosphatidylinositol-3-kinase (PI3´-kinase) with FAK. We recently reported that intervention to reverse hepatic insulin resistance in an obese rat model was associated with markedly increased tyrosine phosphorylation of FAK in liver. To test the hypothesis that FAK plays a regulatory role in hepatic insulin action, we overexpressed wild-type (W/T), a kinase inactive (K/R) or a c- We conclude that FAK regulates the activity of Akt/PKB and GSK-3β and the association of GSK-3β with FAK to influence insulin-mediated glycogen synthesis in hepatocytes and thus may play an important role in hepatic insulin action. Insulin action may be subject to secondary regulation by the integrin signaling pathway, ensuring that these growth and differentiationpromoting pathways act in a coordinated and/or complimentary manner.
(GSK-3β), the regulatory enzyme immediately upstream of GS, by serine phosphorylation We conclude that FAK regulates the activity of Akt/PKB and GSK-3β and the association of GSK-3β with FAK to influence insulin-mediated glycogen synthesis in hepatocytes and thus may play an important role in hepatic insulin action. Insulin action may be subject to secondary regulation by the integrin signaling pathway, ensuring that these growth and differentiationpromoting pathways act in a coordinated and/or complimentary manner.
INTRODUCTION
Integrins constitute a cell-surface transmembrane receptor family that mediate growth and differentiation-promoting functions upon activation by engagement with basement membrane or other extracellular ligands (1) . Clustering of a number of intracellular signaling proteins at the site of focal contact (focal adhesion complex formation) is a central feature of integrin activation (2, 3) . FAK is a 125kDa cytosolic protein tyrosine kinase, named for its predominant cellular localization within the focal adhesion complex, which is tyrosine phosphorylated and activated upon integrin engagement (4) and which interacts with PI3´-kinase, Shc and Grb2 to promote integrin signaling (5-7).
It has also been shown that the tyrosine phosphorylation state of FAK is regulated in a complex manner by growth factor stimulation and that FAK associates with both the IR and IRS proteins upon insulin stimulation (8) (9) (10) (11) . In the case of platelet-derived growth factor (PDGF) and insulin-like growth factor-I (IGF-I), FAK undergoes tyrosine phosphorylation at low ligand concentrations, but is dephosphorylated at higher concentrations (7) . In addition, the regulation of the tyrosine phosphorylation state of FAK upon insulin stimulation is a function of the level of IR expression (4, 12) , cell type (13) and the adhesion state of the cell (9, 14) . It has also previously been reported that integrin engagement stimulates both IRS-1-associated PI3´-kinase activity and Akt/protein kinase B (Akt/PKB) activity (15) , which are important steps in insulin´s action to stimulate glucose transport and glycogen synthesis. Integrin engagement appears to play a stimulatory role in insulin signaling (8) and specifically in insulin-stimulated mitogenesis (16) , suggesting that the state of cell contact is an important regulator of insulin action.
In light of the above data, it is important to establish the role of FAK in the regulation of insulin action. Hitherto, the tyrosine phosphorylation state of FAK in response to insulin administration in vivo was unknown. However, we recently showed that in the liver of healthy Sprague-Dawley rats, FAK rapidly undergoes tyrosine phosphorylation upon insulin stimulation under euglycemic conditions in vivo (14) . Moreover, we observed that when insulin resistance was ameliorated in obese Zucker rats by administration of an adenoviral construct containing cDNA encoding for a soluble inhibitor of tumor necrosis factor-α (TNF-i), this was associated with a consistent increase (> 4-fold) in the tyrosine phosphorylation state of a 125 kDa protein, the identity of which was subsequently confirmed to be FAK (14) . Using HepG2 cells, a human hepatoma cell line, we further showed that pre-treatment with TNF-α abolished insulin-stimulated tyrosine phosphorylation of FAK, without altering IR abundance or IR tyrosine phosphorylation.
In light of the above data, we undertook the present study in order to test the hypothesis that FAK plays an important role in the regulation of hepatic insulin signaling and insulin action. In the present work, we employ mutant FAK constructs overexpressed in HepG2 hepatoma cells and show that both the focal adhesion targeting property and tyrosine kinase activity of FAK are essential for insulin-mediated stimulation of glycogen synthesis and that FAK acts to promote insulin action downstream of PI3´-kinase, by a specific interaction with GSK-3β and Akt/PKB.
EXPERIMENTAL PROCEDURES

Materials and supplies:
Antibodies to FAK and GSK-3β were obtained from Transduction Laboratories (Lexington, KY). Anti-IR β-subunit, anti-IRS-1 and anti-p85 polyclonal antibodies were obtained from Upstate Biotechnology Inc. (Lake Placid, NY). Antibody to Akt and antiphospho-specific Akt polyclonal antibody which recognizes serine 473 phosphorylated Akt as well as anti-phospho-specific GSK-3β polyclonal antibody which recognizes serine 9 phosphorylated GSK-3β were from Cell Signaling Technology (Beverly, MA). Antibody against phosphotyrosine (pY99) was purchased from Santa Cruz Biotechnology Inc. (Santa Cruz, CA).
Chemiluminescence kit, Protein A/G-conjugated agarose beads, HRP-conjugated anti-mouse and anti-rabbit secondary antibodies were all purchased from Pierce (Rockford, IL NaCl, 0.5% deoxycholate, and 1% Nonidet P-40) containing aprotinin (20 µg/ml), leupeptin (20 µg/ml), 1 mM sodium orthovanadate, 10 mM NaF, 10 mM sodium pyrophosphate, 1 mM phenylmethylsulfonylfloride) was then added and the cells were scraped off and transferred to 1.5 ml microcentrifugation tubes. They were incubated on ice for 40 min and vortexed frequently. After centrifugation at 100,000 x g for 30 min at 4 °C, the clarified supernatants were aliquoted with RIPA lysis buffer to equal protein content (Bio-Rad).
Determination of the rate of cell growth and cell morphology: Cells were suspended at 0. Co-immunoprecipitation studies: Cell lysates were prepared as described above. Samples containing 500 µg of protein were precleared for 2hr at 4°C with protein G-sepharose that had previously been washed 3 times with lysis buffer, and were immunoprecipitated overnight at 4°C with 1 µg of monoclonal anti-GSK-3β or anti-Akt/PKB antibody. Protein G-sepharose (40 µl of beads in suspension) was added, and the incubation was continued for 3 hr. After washing the precipitates 3 times with lysis buffer, 20 µl of Laemmli stopping buffer was added to each pellet and the samples were placed in boiling water for 10 min before SDS-PAGE and immunoblotting. When the blots were probed with the monoclonal anti-FAK antibody, HRPconjugated mouse antibody was used as secondary antibody. The blots were then stripped by incubation in 100 mM β-mercaptoethanol, 2% SDS, 62.5 mM Tris-HCl, pH 6.7, at 50°C for 30 min with agitation, followed by thorough rinsing, blocking, and reprobing with monoclonal GSK-3β or polyclonal Akt/PKB antibody. hours at -20°C followed by centrifugation at 1100 x g for 10 min. This step was then repeated.
Measurement of glycogen synthesis in
After the pellets had been re-dissolved in distilled water, the samples were precipitated again as described above. The amount of incorporated radioactivity was determined by liquid scintillation counting.
Measurement of glycogen synthase (GS) activity in HepG2 cells: GS activity was determined
by a modification of previously described methods (21, 22) . HepG2 cells transfected with FAK mutants were incubated in serum free medium overnight, followed by the addition of 100 nM insulin or saline for 10 min at 37 °C. After washing with PBS, cells were scraped into 500 µl of GS assay buffer (50 mM Tris-HCL, pH 7.8, 100 mM NaF, 20 mM EDTA, 0.5% glycogen, 1 mM PMSF, 1 mM benzamidine, 10 µg/ml leupeptin, 10 µg/ml aprotinin) and incubated on ice for 40 min with frequent mixing. After centrifugation at 100,000 x g for 30 min at 4 °C, the clarified supernatants were aliquoted with GS assay buffer to equal protein content (Bio-Rad). To measure GS activity, 50 µl of supernatant (4 µg protein per µl) were added to an equal volume of GS buffer containing 2 µCi/ml UDP- 
RESULTS
Overexpression of W/T and mutant FAK constructs in
Insulin-stimulated GS activity is impaired in HepG2 cells transfected with FAT and K/R FAK mutants:
In order to determine the mechanism of the inhibition of insulin-stimulated glycogen synthesis in FAT and K/R mutant cells, GS activity was assayed. An in vitro assay in which C 14 -UDP-glucose incorporation into glycogen was determined in the presence of GS precipitated from HepG2 cells overexpressing the W/T and mutant forms of FAK was employed.
The data are shown in Figure 4 and demonstrate that incremental insulin-stimulated GS activity was significantly impaired in the presence of the 2 mutant FAK constructs. In NON, CMV2 and W/T preparations, insulin stimulation led to a 2.3, 2.1 and 2.1-fold increase in GS activity respectively. In contrast, in the preparations overexpressing FAT and K/R, GS activity increased by 1.7 and 1.3 fold respectively (p <0.05 versus NON, CMV2 and W/T). There was a significant difference between basal and insulin-stimulated GS activity in FAT (p <0.05), but not in K/R cells. Basal non-insulin-stimulated GS activity was similar in all preparations (not shown).
Interestingly, the increment in insulin-stimulated GS activity in W/T cells was similar to that seen in control preparations, which paralleled the results for glycogen synthesis seen in Figure 3 .
Overexpressing FAT and K/R FAK mutants impair insulin-mediated GSK-3β-ser 9 phosphorylation in HepG2 cells: Activation of GS is a rate-limiting step in glycogen synthesis, and GS is regulated by both allosteric and phosphorylation-dephosphorylation mechanisms (32) .
There is evidence that inhibition of GSK-3β activity by insulin-mediated serine phosphorylation is a key regulatory mechanism of activation of GS upon insulin stimulation (33) . Insulin treatment results in phosphorylation on Ser 9 of GSK-3β, leading to enzyme inactivation, thus releasing GS from its inhibitory influence (34) (35) (36) . To determine whether the observed effect of FAT or K/R FAK on glycogen synthesis was accompanied by changes in the activation state of GSK-3β, the effect of insulin on ser 9 phosphorylation of GSK-3β was examined. Nontransfected HepG2 cells and cells transfected with FAK constructs were exposed to insulin for 10 min. GSK-3β was then immunoprecipitated and ser 9 -phosphorylation was analyzed using an anti-GSK-3β−ser 9 antibody. As shown in Figure 5A , insulin stimulation led to a marked increase in GSK-3β ser 9 (Fig. 6A) . These data are shown quantitatively in Figure 6B and demonstrate that the effect of FAT or K/R FAK on insulin-mediated GSK-3β ser 9 phosphorylation is also accompanied by increased insulin-stimulated association between FAK and GSK-3β, These findings suggest that a transient association between FAK and GSK-3β is necessary for insulin action to promote glycogen synthesis and that failure to terminate this association appropriately may lead to impaired insulin action, at least on glycogen synthesis.
Insulin-mediated Akt/PKB-ser 473 phosphorylation is impaired in HepG2 cells overexpressing FAT and K/R mutants:
Since Akt/PKB is known to be the upstream regulator of GSK-3β in insulin signaling to glycogen synthesis (37), we analyzed the phosphorylation state of one key residue in Akt/PKB, namely ser 473 , using a phosphospecific antibody.
Phosphorylation of ser 473 of Akt/PKB occurs as a result of insulin stimulation (38) . As shown in Figure 6A , there was a marked increase in phosphorylation of ser 473 in response to exposure to insulin in HepG2 cells transfected with either W/T FAK or vector alone, as well as in untransfected cells. However, similar to the effect on ser 9 phosphorylation of GSK-3β presented above, the insulin-stimulated increase in Akt/PKB ser 473 phosphorylation was significantly impaired in HepG2 cells overexpressing FAT or K/R-FAK mutants, compared with that seen with W/T FAK, vector alone, or in untransfected cells (Fig 7A) . These data are shown quantitatively in Figure 7B . There was no immunoprecipitable association between FAK and Akt/PKB, either in the basal or insulin-stimulated state (data not shown). Insulin is a pleiotropic hormone which both effects and affects a broad range of biologic functions including regulation of glucose and fat metabolism, protein synthesis, cytoskeletal rearrangement, cell growth and differentiation (46) . It is now accepted that insulin-mediated glycogen synthesis utilizes a signaling cascade involving PI3´-kinase (47, 48) and the downstream effector Akt/PKB (49) (50) (51) . The ability of insulin to regulate the activation state of FAK was, however, a recent observation (9, 12) . Most available information in the literature focuses on the role of FAK in insulin-mediated effects on the cytoskeleton (13, 42) . As a result, the precise role of FAK in insulin´s other metabolic actions remains poorly understood. Crosstalk between integrin and insulin signaling is suggested by the finding that insulin-stimulated DNA synthesis is modulated by engagement of α V β 3 integrin (16, 52, 53) . It has been shown that insulin promotes association of IRS-1 with integrin (16) and also that tyrosine phosphorylated IR rapidly associate with integrin at focal adhesion contacts (53) . Furthermore, cell adhesion and integrin engagement promote insulin's ability to activate PI3´-kinase (7). Integrin also modulates the insulin and insulin-like growth factor-1 signaling pathways by regulating cellular IRS-1 mRNA expression and the pathway of FAK-mediated signaling to JNK appears to be involved in this process (11) . Evidence in the present work supporting a role for an interaction between FAK and GSK-3β in the regulation of glycogen synthesis by insulin includes the following: Firstly, overexpression of FAT or K/R mutant FAK abolished insulin-stimulated glucose incorporation into glycogen, was accompanied by significantly reduced serine phosphorylation of both Akt/PKB and GSK-3β, and significantly increased the insulin-stimulated co-immunoprecipitation of FAK with GSK-3β.
IR-β and IRS
The regulation of the serine phosphorylation state of GSK-3β by FAK may thus be secondary to its ability to regulate Akt/PKB activation. Insulin-mediated serine phosphorylation of GSK-3β
was upregulated in W/T overexpression, while both Akt/PKB phosphorylation and glycogen synthesis were unchanged. Possible explanations for this finding include additional regulation of GS by Akt/PKB through a mechanism other than via inhibition of GSK-3β alone, or that endogenous levels of FAK permit activation of Akt/PKB and inhibition of GSK-3β sufficient for maximum insulin-stimulated glycogen synthesis in this system. It has previously been reported that Akt/PKB and GSK-3β can be activated by PI3´-kinase-independent mechanisms (54, 55) .
Initially, the observed association between FAK and GSK-3β in the basal state was unexpected.
However, Ding et al have reported that β-catenin is a substrate of GSK-3β in the Wnt signaling pathway (56) . β-catenin is involved in mediation of cell adhesion and transcription and associates with focal adhesion proteins, including FAK (57, 58) . However, activation of the Wnt signaling pathway does not regulate GS activity, and does not lead to the phosphorylation of serine 9 of GSK-3β nor activation of Akt/PKB which occur following insulin stimulation. Thus, the association between FAK and GSK-3β may involve intermediary proteins in more than one signaling pathway.
Although the basal association between FAK and GSK-3β was increased, this was not further disproportionately stimulated by exposure to insulin in W/T cells. By contrast, the abolition of insulin-stimulated glycogen synthesis seen in cells overexpressing FAT and K/R mutants was associated in both cases with a clear insulin-mediated increase in association between FAK and GSK-3β. Interestingly, in the case of FAT, the increased association involved only endogenous FAK and not FAT itself. This suggests that either localization to the focal adhesion complex is required for the subsequent insulin-stimulated association-dissociation to occur, or that FAT is acting as a dominant negative at a step outside the focal adhesion complex, thereby inhibiting the required dissociation of even normally localized FAK from GSK-3β.
Since the phosphate groups on GS turn over rapidly (59) , it has been proposed that inhibition of GSK-3β serves as a physiologically relevant mechanism for regulating GS activity. The regulation of GSK-3β by insulin has been shown to be mediated by Akt/PKB (60, 61) . Upon insulin stimulation, the serine 473 residue of Akt/PKB is phosphorylated and Akt/PKB is activated (62) . Akt/PKB has been implicated as a mediator of metabolic responses to insulin, including GS activation (63) . Subsequently, GSK-3β is phosphorylated on serine 9 , which leads to a decrease in GSK-3β activity (61, 64) . Although this has usually been detected as a 50-70% drop, it is apparently sufficient to relieve the inhibition of GS and allow glycogen synthesis to proceed in an insulin-responsive manner (56) . Therefore further potentiation in Akt/PKB serine phosphorylation might not have led to increased glycogen synthesis. Apparently, GSK-3β inhibition alone is not sufficient for the dephosphorylation and activation of GS (32) . Our data suggest that FAK mutants may potentially inhibit insulin-stimulated phosphatase activity and that FAK plays a regulatory role in insulin-stimulated glycogen synthesis and that this is achieved through an interaction between FAK, Akt/PKB and GSK-3β.
The fact that incremental insulin-stimulated GS activity was partially, but significantly, attenuated in the presence of FAT and K/R mutants indicates that impaired regulation of GS activity is at least partly responsible for the reduction in insulin-stimulated glycogen synthesis seen in the presence of these mutants.
The mechanism whereby these FAK mutants inhibit the ability of insulin to induce phosphorylation of Akt/PKB remains unclear. It is possible that endogenous FAK interacts with an unidentified substrate that is necessary for the interaction between PI3´-kinase and Akt/PKB and that mutant FAK exerts a dominant negative effect on endogenous FAK. A similar dissociation between PI3´-kinase activity and activation of Akt/PKB has previously been reported (65, 66) . Lin et al found that the protein kinase C (PKC) activator phorbol dibutyrate decreased the ability of insulin to phosphorylate both Akt/PKB and GSK-3β by 90% and 35% respectively in rat skeletal muscle, while PI3´-kinase activation was unaffected (65) . Also,
Matsumoto et al reported that in CHO cells and L6 myocytes, expression of kinase-defective
PKC-δ inhibited insulin-mediated phosphorylation and activation of Akt/PKB, while having no inhibitory effect on phosphorylation or activity of PI3´-kinase (66) . Whether PKC is involved in the downstream regulation of insulin signaling by FAK remains to be investigated.
We also found that the effect of overexpression of these FAK constructs on glycogen synthesis was unaccompanied by changes in the tyrosine phosphorylation state of either the IR-β−subunit or IRS-1, nor was the level of expression of either of these upstream proteins affected.
Importantly, IRS-1-associated PI3´-kinase activity was also unaltered. In this respect, our findings differ from those of Lebrun et al (10) , who reported that FAK interacts directly with IRS-1 and regulates IRS-1-associated PI3´-kinase activity. The following may be offered to explain this discrepancy: Firstly, the studies were performed in different cell systems, FAK -/-cells and DA2 cells being of fibroblast lineage, while HepG2 cells are insulin-responsive human hepatoma cells (9) . Secondly, Lebrun et al studied cells that were in the suspended state for 2 hours (11), while we utilized attached cells. Since the nature of the cross-talk between insulin/IGF-I receptors and FAK is dependent upon cell architecture, the interaction of the insulin/IGF-I signaling system with integrin will vary accordingly (9) . Finally, Goode et al (67) have already reported that GSK-3β can be phosphorylated by certain isoforms of PKC in vitro.
Bogdanovic et al (68) also reported that under conditions of insulin resistance PKC downregulates Akt/PKB and that this is unaccompanied by a change in PI3´-kinase activity. We hypothesize that the FAK mutants used in this study may also down regulate Akt/PKB activity.
Moreover, the increased association of FAK mutants with GSK-3β upon insulin stimulation emphasizes this down regulation. Possibly, this downregulation is PKC-mediated, leading to reduced phosphorylation of GSK-3β. However, further studies will be required to address this issue.
The effect of these FAK mutants to inhibit insulin-mediated glycogen synthesis in this adherent cell system appeared to parallel their inhibition of the insulin-mediated dephosphorylation of 
